Myriad Genetics (NASDAQ: MYGN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Myriad Genetics Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Myriad Genetics Company Info
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
News & Analysis
The genetic-testing company announced an acquisition and lowered its guidance.
But there were a few encouraging signs for the molecular-diagnostics company.
Coronavirus testing is up, but the pandemic has hammered demand for Myriad's hereditary cancer tests.
Have these growth stocks bottomed out? That's probably the wrong question to ask.
More babies are born in summer and early fall than other times of year, meaning mothers-to-be are likely undergoing prenatal testing now. Can investors profit?
The molecular diagnostics company also delivered an earnings miss, and its stock plunged.
The molecular diagnostics company's latest quarterly results weren't anywhere close to what Wall Street expected.
Poor earnings took many stocks lower Tuesday.
MYGN earnings call for the period ending September 30, 2021.
MYGN earnings call for the period ending June 30, 2021.
MYGN earnings call for the period ending December 31, 2020.
MYGN earnings call for the period ending September 30, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.